Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-dense FEC followed by dose-dense ixabepilone with G-CSF in neoadjuvant ER-negative breast cancer
2008-000486-29Phase 2Active
- Sponsor
- Consorzio Oncotech
- Start
- Dec 2008
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ixabepilone, fluorouracil, epirubicin, cyclophosphamide and filgrastim in breast cancer and estrogen receptor negative breast cancer, sponsored by Consorzio Oncotech. Primary endpoint: Treatment tolerability. Started Dec 2008; status: active.
02
Drugs
ixabepilonefluorouracilepirubicincyclophosphamidefilgrastim
03
Conditions
breast cancerestrogen receptor negative breast cancer
Beyond the preview
Go deeper on 2008-000486-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000486-29.